350,000 Shares in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Acquired by Boxer Capital Management LLC

Boxer Capital Management LLC acquired a new stake in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 350,000 shares of the company's stock, valued at approximately $7,483,000. Boxer Capital Management LLC owned 2.33% of Jasper Therapeutics at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Wells Fargo & Company MN increased its holdings in Jasper Therapeutics by 106.7% in the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after acquiring an additional 3,828 shares during the last quarter. EntryPoint Capital LLC purchased a new position in shares of Jasper Therapeutics in the fourth quarter worth about $223,000. Jane Street Group LLC purchased a new stake in shares of Jasper Therapeutics during the 3rd quarter valued at approximately $251,000. Barclays PLC boosted its holdings in Jasper Therapeutics by 320.7% in the 3rd quarter. Barclays PLC now owns 16,146 shares of the company's stock worth $304,000 after buying an additional 12,308 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in Jasper Therapeutics by 239.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company's stock valued at $308,000 after buying an additional 11,567 shares in the last quarter. 79.85% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

JSPR has been the subject of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Jasper Therapeutics in a report on Tuesday, March 11th. UBS Group started coverage on shares of Jasper Therapeutics in a research report on Thursday, February 13th. They issued a "buy" rating and a $38.00 price objective for the company. JMP Securities reaffirmed a "market outperform" rating and set a $70.00 target price on shares of Jasper Therapeutics in a report on Monday, January 6th. Finally, Royal Bank of Canada cut their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a report on Thursday, January 9th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $62.50.

Jasper Therapeutics Stock Performance

NASDAQ:JSPR traded down $0.18 during trading hours on Monday, reaching $5.23. The company's stock had a trading volume of 114,228 shares, compared to its average volume of 287,704. The firm has a 50-day simple moving average of $4.77 and a 200-day simple moving average of $11.97. Jasper Therapeutics, Inc. has a 1 year low of $3.13 and a 1 year high of $26.84. The firm has a market capitalization of $78.57 million, a price-to-earnings ratio of -1.10 and a beta of 2.55.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.35). Equities analysts anticipate that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current fiscal year.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.